Impact of CDK4/6 Inhibitors on Health-Related Quality of Life Outcomes in Patients With Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

    Takako Kiener, Kevin H. Li, Erin Chiang, Quang A. Le
    Studysummary This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →